Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
type: MedicalStudy
description: Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
status: COMPLETED
study design: INTERVENTIONAL
phase: PHASE3
start date: 2008-07-29
end date: 2012-01-31
license: https://creativecommons.org/publicdomain/zero/1.0/
source: https://clinicaltrials.gov/study/NCT00678886
source organization: US National Library of Medicine
publisher: AI Analytics
sponsor: GlaxoSmithKline
study subject: Diabetes Mellitus, Type 1
keywords: PHASE3
keywords: INTERVENTIONAL
keywords: COMPLETED
keywords: Diabetes Mellitus, Type 1

AI Analytics
type: Organization